Ryan Watts, Denali CEO (Flagship Pioneering via YouTube)

Bio­gen opts in­to De­nali Alzheimer's pro­gram tar­get­ing amy­loid be­ta plaque

Bio­gen is tak­ing an­oth­er step in its neu­rode­gen­er­a­tive dis­ease col­lab­o­ra­tion with De­nali Ther­a­peu­tics.

The big biotech an­nounced Wednes­day it is pick­ing up an op­tion for a pre­clin­i­cal Alzheimer’s pro­gram from De­nali, tak­ing over all de­vel­op­ment ac­tiv­i­ties and costs. In ex­change, De­nali gets some cash — for an undis­closed amount — and the promise of some mile­stones down the road.

Bio­gen and De­nali spokes­peo­ple both de­clined to pro­vide spe­cif­ic fi­nan­cial de­tails for the op­tion pay­ment and mile­stones. Ad­di­tion­al­ly, nei­ther com­pa­ny dis­closed this op­tion’s fi­nan­cials when they signed the col­lab­o­ra­tion in Au­gust 2020.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.